“…This efficient ringclosing strategy was recently used to prepare more than 20 C-13modified bryostatin analogues for evaluation as protein kinase C modulators (Scheme 7). 21 Several tested analogues were found to display good clinical potential for enhancing antigen-targeted immunotherapies. The development of a novel bifunctional trichlorosilane reagent 22 not only improved their previous route for the A-ring fragment but also provided access to a structurally more simplified des-A-ring analogue 40, which retains excellent affinity for several protein kinase C isoforms as compared to the parent natural product.…”